| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Proteogenomics | 15 | 2025 | 110 | 2.780 |
Why?
|
| Breast Neoplasms | 19 | 2025 | 2681 | 2.000 |
Why?
|
| Drug Resistance, Neoplasm | 6 | 2025 | 816 | 1.160 |
Why?
|
| Estrogen Receptor alpha | 6 | 2023 | 439 | 0.970 |
Why?
|
| Receptors, Estrogen | 6 | 2025 | 741 | 0.830 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2021 | 265 | 0.720 |
Why?
|
| Triple Negative Breast Neoplasms | 5 | 2025 | 274 | 0.690 |
Why?
|
| Endocytosis | 3 | 2011 | 126 | 0.680 |
Why?
|
| Proteomics | 12 | 2025 | 596 | 0.630 |
Why?
|
| Cyclin-Dependent Kinase 6 | 4 | 2025 | 49 | 0.630 |
Why?
|
| Cyclin-Dependent Kinase 4 | 4 | 2025 | 64 | 0.620 |
Why?
|
| Neoplasms | 6 | 2024 | 2961 | 0.620 |
Why?
|
| Antineoplastic Agents | 4 | 2024 | 1829 | 0.580 |
Why?
|
| Gene Fusion | 1 | 2018 | 60 | 0.570 |
Why?
|
| Receptors, Interleukin-5 | 2 | 2008 | 5 | 0.550 |
Why?
|
| Neurofibromin 1 | 3 | 2025 | 50 | 0.440 |
Why?
|
| Signal Transduction | 9 | 2025 | 4720 | 0.420 |
Why?
|
| Biomarkers, Tumor | 5 | 2025 | 1679 | 0.420 |
Why?
|
| Lysine | 2 | 2011 | 185 | 0.400 |
Why?
|
| Ubiquitination | 2 | 2021 | 172 | 0.380 |
Why?
|
| Epithelial-Mesenchymal Transition | 4 | 2025 | 241 | 0.370 |
Why?
|
| Cytokine Receptor Common beta Subunit | 1 | 2011 | 1 | 0.370 |
Why?
|
| Janus Kinase 1 | 1 | 2011 | 11 | 0.370 |
Why?
|
| Janus Kinase 2 | 1 | 2011 | 134 | 0.330 |
Why?
|
| Eosinophils | 2 | 2008 | 122 | 0.330 |
Why?
|
| Molecular Targeted Therapy | 3 | 2024 | 403 | 0.330 |
Why?
|
| Protein Kinase Inhibitors | 5 | 2025 | 608 | 0.320 |
Why?
|
| Precision Medicine | 2 | 2023 | 360 | 0.300 |
Why?
|
| Transferrin | 1 | 2008 | 47 | 0.290 |
Why?
|
| Mutation | 9 | 2025 | 6243 | 0.290 |
Why?
|
| src-Family Kinases | 2 | 2016 | 94 | 0.280 |
Why?
|
| Humans | 41 | 2025 | 132201 | 0.270 |
Why?
|
| Neoadjuvant Therapy | 3 | 2025 | 400 | 0.270 |
Why?
|
| Cell Line, Tumor | 9 | 2025 | 3691 | 0.270 |
Why?
|
| Protein Kinases | 3 | 2025 | 331 | 0.270 |
Why?
|
| Janus Kinases | 1 | 2007 | 32 | 0.260 |
Why?
|
| Female | 27 | 2025 | 70754 | 0.250 |
Why?
|
| Ubiquitin | 1 | 2007 | 141 | 0.250 |
Why?
|
| Receptor, ErbB-2 | 3 | 2025 | 549 | 0.230 |
Why?
|
| Software | 3 | 2025 | 731 | 0.230 |
Why?
|
| Zona Pellucida Glycoproteins | 1 | 2025 | 8 | 0.230 |
Why?
|
| Phosphorylation | 6 | 2025 | 1611 | 0.220 |
Why?
|
| Phosphoproteins | 2 | 2025 | 443 | 0.220 |
Why?
|
| Down-Regulation | 1 | 2007 | 679 | 0.220 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 2022 | 92 | 0.220 |
Why?
|
| Phenylthiohydantoin | 1 | 2024 | 15 | 0.220 |
Why?
|
| Benzamides | 1 | 2024 | 124 | 0.210 |
Why?
|
| Paclitaxel | 1 | 2024 | 140 | 0.210 |
Why?
|
| Nitriles | 1 | 2024 | 155 | 0.210 |
Why?
|
| Xenograft Model Antitumor Assays | 5 | 2025 | 998 | 0.200 |
Why?
|
| Lung Neoplasms | 2 | 2025 | 1541 | 0.200 |
Why?
|
| Computational Biology | 2 | 2025 | 876 | 0.200 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2025 | 361 | 0.200 |
Why?
|
| Cell Proliferation | 5 | 2025 | 2511 | 0.200 |
Why?
|
| Endometrial Neoplasms | 1 | 2023 | 112 | 0.190 |
Why?
|
| Mass Spectrometry | 2 | 2021 | 356 | 0.180 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2022 | 75 | 0.180 |
Why?
|
| Tumor Microenvironment | 4 | 2024 | 689 | 0.180 |
Why?
|
| Proteome | 1 | 2023 | 279 | 0.180 |
Why?
|
| Metformin | 1 | 2023 | 166 | 0.180 |
Why?
|
| Receptors, Androgen | 1 | 2024 | 410 | 0.170 |
Why?
|
| Machine Learning | 1 | 2024 | 348 | 0.170 |
Why?
|
| Gene Expression Profiling | 3 | 2024 | 1882 | 0.170 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2025 | 541 | 0.170 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2024 | 1348 | 0.160 |
Why?
|
| Prognosis | 3 | 2025 | 5015 | 0.160 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2021 | 232 | 0.160 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2021 | 2062 | 0.150 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2021 | 127 | 0.150 |
Why?
|
| Claudins | 1 | 2018 | 31 | 0.150 |
Why?
|
| Genomics | 4 | 2023 | 1652 | 0.150 |
Why?
|
| Databases, Factual | 1 | 2024 | 1234 | 0.150 |
Why?
|
| Adenocarcinoma | 1 | 2025 | 1018 | 0.140 |
Why?
|
| Mitosis | 1 | 2018 | 198 | 0.140 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2025 | 899 | 0.140 |
Why?
|
| MutL Proteins | 1 | 2017 | 19 | 0.140 |
Why?
|
| Carcinogenesis | 1 | 2020 | 359 | 0.140 |
Why?
|
| Checkpoint Kinase 2 | 1 | 2017 | 35 | 0.140 |
Why?
|
| Protein Binding | 3 | 2021 | 1733 | 0.130 |
Why?
|
| Transfection | 1 | 2018 | 996 | 0.130 |
Why?
|
| Papillomavirus Infections | 1 | 2021 | 385 | 0.120 |
Why?
|
| Muscle Proteins | 1 | 2018 | 404 | 0.120 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2021 | 768 | 0.120 |
Why?
|
| Mammary Glands, Human | 1 | 2016 | 81 | 0.120 |
Why?
|
| Cell Movement | 1 | 2018 | 890 | 0.110 |
Why?
|
| Mice, Nude | 3 | 2021 | 755 | 0.110 |
Why?
|
| MCF-7 Cells | 3 | 2020 | 217 | 0.110 |
Why?
|
| DNA Copy Number Variations | 1 | 2019 | 1034 | 0.100 |
Why?
|
| Pyridines | 2 | 2025 | 249 | 0.100 |
Why?
|
| Liver Neoplasms | 1 | 2023 | 1382 | 0.100 |
Why?
|
| Piperazines | 2 | 2025 | 255 | 0.100 |
Why?
|
| Animals | 10 | 2025 | 34842 | 0.100 |
Why?
|
| Aged | 7 | 2025 | 21456 | 0.100 |
Why?
|
| Immunotherapy | 3 | 2024 | 749 | 0.090 |
Why?
|
| Neoplasm Invasiveness | 2 | 2025 | 665 | 0.090 |
Why?
|
| Mice | 7 | 2025 | 18504 | 0.090 |
Why?
|
| Endosomes | 1 | 2011 | 65 | 0.090 |
Why?
|
| Middle Aged | 7 | 2025 | 29007 | 0.080 |
Why?
|
| Protein Transport | 1 | 2011 | 370 | 0.080 |
Why?
|
| HEK293 Cells | 1 | 2011 | 799 | 0.070 |
Why?
|
| Pulmonary Alveolar Proteinosis | 1 | 2008 | 6 | 0.070 |
Why?
|
| Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2008 | 8 | 0.070 |
Why?
|
| Leukemia, Erythroblastic, Acute | 1 | 2008 | 12 | 0.070 |
Why?
|
| Clathrin | 1 | 2008 | 24 | 0.070 |
Why?
|
| Cholera Toxin | 1 | 2008 | 51 | 0.070 |
Why?
|
| Interleukin-5 | 1 | 2008 | 48 | 0.070 |
Why?
|
| Cell Cycle | 2 | 2023 | 607 | 0.070 |
Why?
|
| Chromosomes, Human, X | 1 | 2008 | 157 | 0.070 |
Why?
|
| Treatment Outcome | 1 | 2023 | 13028 | 0.070 |
Why?
|
| p21-Activated Kinases | 2 | 2018 | 56 | 0.070 |
Why?
|
| Tyrphostins | 1 | 2007 | 13 | 0.070 |
Why?
|
| ErbB Receptors | 2 | 2021 | 295 | 0.070 |
Why?
|
| RNA, Messenger | 2 | 2023 | 2679 | 0.060 |
Why?
|
| Apoptosis | 2 | 2024 | 1901 | 0.060 |
Why?
|
| Cell Membrane | 1 | 2008 | 472 | 0.060 |
Why?
|
| Cytoplasm | 1 | 2007 | 269 | 0.060 |
Why?
|
| Flow Cytometry | 1 | 2008 | 802 | 0.060 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2007 | 251 | 0.060 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2022 | 772 | 0.060 |
Why?
|
| Databases, Protein | 1 | 2025 | 62 | 0.060 |
Why?
|
| ATPases Associated with Diverse Cellular Activities | 1 | 2025 | 81 | 0.060 |
Why?
|
| Cyclin D1 | 1 | 2025 | 113 | 0.060 |
Why?
|
| Aged, 80 and over | 3 | 2021 | 7123 | 0.060 |
Why?
|
| Chromosomal Instability | 1 | 2025 | 60 | 0.060 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2022 | 766 | 0.060 |
Why?
|
| Single-Chain Antibodies | 1 | 2025 | 44 | 0.060 |
Why?
|
| Trastuzumab | 1 | 2025 | 154 | 0.060 |
Why?
|
| Protein Interaction Maps | 1 | 2024 | 90 | 0.050 |
Why?
|
| Benchmarking | 1 | 2025 | 138 | 0.050 |
Why?
|
| Cell Adhesion Molecules | 1 | 2025 | 234 | 0.050 |
Why?
|
| Phosphopeptides | 1 | 2023 | 25 | 0.050 |
Why?
|
| Enzyme Inhibitors | 1 | 2007 | 589 | 0.050 |
Why?
|
| Knowledge Bases | 1 | 2023 | 40 | 0.050 |
Why?
|
| Adult | 5 | 2024 | 31600 | 0.050 |
Why?
|
| Disease Models, Animal | 2 | 2025 | 4690 | 0.050 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2024 | 231 | 0.050 |
Why?
|
| NFI Transcription Factors | 1 | 2023 | 50 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2023 | 93 | 0.050 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2024 | 174 | 0.050 |
Why?
|
| Purines | 1 | 2023 | 113 | 0.050 |
Why?
|
| Environmental Exposure | 1 | 2025 | 234 | 0.050 |
Why?
|
| X-ray Repair Cross Complementing Protein 1 | 1 | 2022 | 20 | 0.050 |
Why?
|
| Epidermal Growth Factor | 1 | 2023 | 119 | 0.050 |
Why?
|
| Carboplatin | 1 | 2022 | 85 | 0.050 |
Why?
|
| Ki-67 Antigen | 1 | 2022 | 116 | 0.050 |
Why?
|
| Gene Regulatory Networks | 1 | 2024 | 386 | 0.050 |
Why?
|
| beta Catenin | 1 | 2023 | 227 | 0.050 |
Why?
|
| Cell Division | 1 | 2023 | 744 | 0.050 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 1 | 2021 | 19 | 0.050 |
Why?
|
| Antigens, Neoplasm | 1 | 2024 | 402 | 0.050 |
Why?
|
| Cell Line | 1 | 2007 | 2724 | 0.050 |
Why?
|
| GTP Phosphohydrolases | 1 | 2022 | 156 | 0.040 |
Why?
|
| Models, Biological | 1 | 2007 | 1445 | 0.040 |
Why?
|
| Receptor Tyrosine Kinase-like Orphan Receptors | 1 | 2021 | 36 | 0.040 |
Why?
|
| APOBEC Deaminases | 1 | 2020 | 7 | 0.040 |
Why?
|
| Acetylation | 1 | 2021 | 191 | 0.040 |
Why?
|
| Cells, Cultured | 1 | 2007 | 3046 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2023 | 502 | 0.040 |
Why?
|
| Peptides | 1 | 2024 | 844 | 0.040 |
Why?
|
| Retinoblastoma Protein | 1 | 2020 | 83 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2020 | 5173 | 0.040 |
Why?
|
| Cluster Analysis | 1 | 2021 | 430 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 1 | 2021 | 1045 | 0.040 |
Why?
|
| Co-Repressor Proteins | 1 | 2020 | 38 | 0.040 |
Why?
|
| Amino Acid Motifs | 1 | 2020 | 206 | 0.040 |
Why?
|
| Estrogen Antagonists | 1 | 2020 | 97 | 0.040 |
Why?
|
| Mutagenesis | 1 | 2020 | 347 | 0.040 |
Why?
|
| ras Proteins | 1 | 2020 | 146 | 0.040 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2019 | 40 | 0.040 |
Why?
|
| Zinc Finger E-box Binding Homeobox 2 | 1 | 2018 | 7 | 0.040 |
Why?
|
| Brazil | 1 | 2019 | 140 | 0.040 |
Why?
|
| Snail Family Transcription Factors | 1 | 2018 | 25 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2024 | 1161 | 0.040 |
Why?
|
| Zinc Finger E-box-Binding Homeobox 1 | 1 | 2018 | 27 | 0.040 |
Why?
|
| Feedback, Physiological | 1 | 2018 | 67 | 0.040 |
Why?
|
| Twist-Related Protein 1 | 1 | 2018 | 39 | 0.040 |
Why?
|
| Mice, SCID | 1 | 2020 | 604 | 0.040 |
Why?
|
| Vimentin | 1 | 2018 | 69 | 0.040 |
Why?
|
| Male | 5 | 2025 | 64979 | 0.040 |
Why?
|
| Tamoxifen | 1 | 2020 | 354 | 0.040 |
Why?
|
| Heterografts | 1 | 2018 | 199 | 0.040 |
Why?
|
| Carrier Proteins | 1 | 2023 | 1049 | 0.030 |
Why?
|
| Algorithms | 1 | 2025 | 1723 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2018 | 398 | 0.030 |
Why?
|
| DNA Damage | 1 | 2020 | 511 | 0.030 |
Why?
|
| DNA Repair | 1 | 2020 | 566 | 0.030 |
Why?
|
| Cell Nucleus | 1 | 2020 | 592 | 0.030 |
Why?
|
| Aromatase Inhibitors | 1 | 2017 | 78 | 0.030 |
Why?
|
| Neoplasm Proteins | 1 | 2021 | 700 | 0.030 |
Why?
|
| Metabolomics | 1 | 2020 | 479 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2017 | 384 | 0.030 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2016 | 24 | 0.030 |
Why?
|
| S-Phase Kinase-Associated Proteins | 1 | 2016 | 20 | 0.030 |
Why?
|
| Transcriptional Activation | 1 | 2018 | 430 | 0.030 |
Why?
|
| Receptor-Interacting Protein Serine-Threonine Kinase 2 | 1 | 2016 | 7 | 0.030 |
Why?
|
| Survival Rate | 1 | 2021 | 2196 | 0.030 |
Why?
|
| Translocation, Genetic | 1 | 2018 | 357 | 0.030 |
Why?
|
| Disease Progression | 1 | 2022 | 2230 | 0.030 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2016 | 86 | 0.030 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2016 | 84 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2019 | 1045 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2016 | 111 | 0.030 |
Why?
|
| Molecular Sequence Annotation | 1 | 2016 | 157 | 0.030 |
Why?
|
| Membrane Proteins | 1 | 2022 | 1595 | 0.030 |
Why?
|
| Calcium-Binding Proteins | 1 | 2016 | 333 | 0.030 |
Why?
|
| Transcriptome | 1 | 2021 | 1125 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2016 | 343 | 0.030 |
Why?
|
| Repressor Proteins | 1 | 2018 | 812 | 0.030 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2016 | 304 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 2018 | 1423 | 0.020 |
Why?
|
| Chromosome Deletion | 1 | 2016 | 655 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2023 | 6569 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2018 | 1284 | 0.020 |
Why?
|
| CD11b Antigen | 1 | 2008 | 39 | 0.020 |
Why?
|
| Pulmonary Surfactants | 1 | 2008 | 46 | 0.020 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2008 | 68 | 0.020 |
Why?
|
| Turner Syndrome | 1 | 2008 | 45 | 0.020 |
Why?
|
| Karyotyping | 1 | 2008 | 317 | 0.020 |
Why?
|
| Monocytes | 1 | 2008 | 342 | 0.020 |
Why?
|
| Young Adult | 1 | 2021 | 9965 | 0.020 |
Why?
|
| Exons | 1 | 2008 | 806 | 0.020 |
Why?
|
| Genotype | 1 | 2008 | 2702 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2008 | 14735 | 0.010 |
Why?
|